Introduction: Chronic inflammatory rheumatic diseases (RDs) trigger high costs for
Results: A total of 9560 subjects, of whom the majority were women (58.1%), were entered into the study; the average age of the study population was 55.3 years. On the index date 12.9% of patients were receiving a biologic DMARD, with adalimumab the most frequently prescribed biologic DMARD (4.7%), followed by etanercept (4.4%). The average total healthcare expenditure was €377.98 per patient per month (patient-month). In the subgroup analysis of healthcare costs according to use of biologics, the total expenditure was €1037.97/ €230.86 patient-month for those receiving/not receiving at least one biologic DMARD. In the subgroup analysis of healthcare costs according to type of biologic used, the total expenditure ranged from €657.61 (golimumab) to €1384.15 (rituximab) patient-month.
Conclusions: A substantial difference in the total costs according to treatment/no
INTRODUCTION
Inflammatory rheumatic diseases (RDs) in general and rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis specifically are chronic systemic disorders which significantly affect patients' quality of life. These pathologies are debilitating and progressive and are associated with severe functional impairment and pain [1, 2] . The worldwide prevalence of RDs is high (about 1%) [3] [4] [5] [6] , with rheumatoid arthritis alone accounting for 0.3-1% of all RDs identified [7] .
First-line treatments for inflammatory RDs include non-steroidal anti-inflammatory drugs, conventional disease-modifying anti-rheumatic drugs (DMARDs; e.g., methotrexate), and corticosteroids; immunosuppressants and systemic corticosteroids are also used [8] [9] [10] [11] [12] [13] 
RESULTS
In total, 12,455 subjects with at least one prescription for a synthetic or biologic Table 1 .
Of the 9560 patients entered into the study, 4153 (43%) reported at least one hospitalization between the index date and the end of the 3-year observation period, among whom were 2655 of the 5989 patients with rheumatoid arthritis (44%), 149 of the 416 patients with ankylosing spondylitis (36%), and 651 of the 1885 patients with psoriatic arthritis (35%). Of the 1300 patients diagnosed with indistinct RD, 698 (54%) reported at least one hospitalization during the index date and the end of the 3-year observation period.
On the index date 12.9% of the study population were receiving a biologic DMARD.
The distribution of all prescriptions on the index date is shown in Table 2 . The total study population of 9560 patients received 9963 prescriptions in the first year (some patients received more [1 biologic DMARD). The and €1050.48 in years 1, 2, and 3, respectively, of the follow-up) (Fig. 1) . The cost of biologic DMARDs was the most important component of this total expenditure, totaling €821.54 (€829.17, €798.27. and €837.17 in years 1, 2, and 3, respectively, of the follow-up). The mean total cost per patient per month in the subgroup of patients who did not have prescriptions for biologic DMARDS was €230.86 (€241.25, €222.58 and €228.74 in years 1, 2, and 3, respectively, of the follow-up). In this subgroup the cost for hospitalization was the most important component of the healthcare expenditure, totaling €94.64 (€99.42, €90.40 and €94.10 in years 1, 2, and 3, respectively, of the follow-up).
The average monthly total cost per patient was also analyzed by stratifying the cohort on Table 5) .
DISCUSSION
Rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis are immune-mediated inflammatory diseases that lead to severe functional impairment, pain and a significant decrease in quality of life. These pathologies determine a relevant economic burden for healthcare services because of significant epidemiological impact [3] [4] [5] [6] . with infliximab). The data on these patients were derived from the administrative databases and Lombardy). The analysis of these authors revealed that the overall mean annual total healthcare expenditure for each patient was of €11,120, of which non-pharmacological costs were €1177 (10.58%) and pharmacological costs were €9943 (89.42%). This total expenditure is significantly higher than that determined in our study population (about €4500 patient-year).
One possible explanation for this difference is that the rate of use of biologic DMARDs was higher in the study of Degli Esposti et al. [23] ; it may be that the cost of these drugs drove up the overall estimate. When we compare the total costs which we estimated in the subgroup of patients who received at least one prescription of biologic DMARDs (around €1000 patient-month) to the estimate of Degli Esposti and colleagues, the costs seem to be more aligned.
Based on our data it appears that a substantial difference exists in the total costs of patients treated with different biologic DMARDS, with a range of about €650 to €1380 patient-month. Beyond the effect of different prices for the different biologic DMARDS, this difference could be explained by an implicit treatment algorithm applied by the clinicians during the study period. For example, it can be assumed that only severe and difficult to treat patients who had been not responding to other classes of biologic DMARDS were prescribed rituximab-the reasoning being that this drug is not recommended as a first-line biologic in clinical guidelines. As a consequence, patients treated with rituximab in our study probably, on average, were in a more advanced stage of disease progression, had received different lines of treatment prior to being placed on rituximab, and had clinically complex disease in comparison to those treated with other Table 4 Mean total monthly costs in the study population (n = treatments, appear to be driving the higher total cost. From another point of view, it seems reasonable to believe that products launched in more recent years were used only in patients who received older treatments first due to the time usually necessary for new products to be considered part of the routine clinical practice.
9560)
Finally, it should be considered that the route of administration (e.g. intravenous vs. subcutaneous) plays an important role in the selection of the treatment as the treating physician must take into account the characteristics of the patient (e.g., presence of disability) and the aggressiveness of the disease. We therefore suggest that the total healthcare costs of the patients treated with different biologic DMARDs in our analysis should be interpreted with caution as they were probably biased by the selection of the patients. The main limitation of the study is the lack of an analysis which adjusts for such baseline characteristics; such an adjustment was not possible given the administrative (and not clinical) nature of the database used.
CONCLUSION
The results of this study shed some light on the healthcare cost of rheumatic patients treated in Italy with biologic DMARDs. The prevalence of comorbidities in our study population was generally low and similar to the distribution reported in the general population, but our results do suggest the existence of a possible correlation between the comorbid condition and need for hospital care. The use of biologic DMARDs was generally low, with only about 13% of the cohort receiving them on the index data, but they had a major impact on the total healthcare expenditure. A substantial difference, however, seems to exists in the total costs of patients treated with different 
